The Impact of Immune Markers on Thymectomy Prognosis in Thymoma-myasthenia Gravis

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2024 Nov 18

PMID 39552868

Authors

Hao Wang

Yang Shi

Zirong Wang

Yu Shi

Yongqiang Chen

Yuan Chen

Affiliations

Soon will be listed here.

Abstract

Background: Research shows that thymoma-associated myasthenia gravis (MG) patients exhibit immunological imbalances, including anomalies in immune indicators. The link between these abnormalities and thymectomy outcomes is not well-understood. This study aims to assess the impact of immunological markers like T helper (Th)17 cells, regulatory T (Treg) cells, CD4 T, CD8 T cells, immunoglobulin (Ig)G, IgA, IgM, IgE, C-reactive protein (CRP), complement C3, and complement C4 on MG prognosis post-thymectomy.

Methods: A retrospective analysis of 163 MG patients undergoing thymectomy between January 2011 and December 2022 at our institution was conducted. We explored the association between preoperative blood immunological markers and prognosis using Kaplan-Meier survival curves and the Cox model. The main goal was to determine if these patients could achieve postoperative sustained remission.

Results: Out of 163 patients, 77 reached sustained remission, 79 showed no change or worsening of MG, including recurrences, and 7 died from severe MG over an average of 68.2 months. A significant finding was that reduced complement C3 levels (P<0.001) correlated with a failure to achieve remission. Other immunological markers, including T cell levels and IgG, showed no prognostic significance.

Conclusions: Complement C3 level is a crucial predictor for long-term remission in thymoma-associated MG post-thymectomy. Patients with lower C3 levels are more likely to experience MG symptom progression post-surgery compared to those with normal levels, indicating its potential as a key prognostic marker.

References

Liu Y, Zhang H, Zhang P, Meng F, Chen Y, Wang Y . Autoimmune regulator expression in thymomas with or without autoimmune disease. Immunol Lett. 2014; 161(1):50-6. DOI: 10.1016/j.imlet.2014.04.008. View

Kim S, Koh I, Minn Y . Pathologic Finding of Thymic Carcinoma Accompanied by Myasthenia Gravis. J Clin Neurol. 2015; 11(4):372-5. PMC: 4596109. DOI: 10.3988/jcn.2015.11.4.372. View

Marx A, Chan J, Coindre J, Detterbeck F, Girard N, Harris N . The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. J Thorac Oncol. 2015; 10(10):1383-95. PMC: 4581965. DOI: 10.1097/JTO.0000000000000654. View

Li J, Zhang Z, Chen Y, Wang Y, Liu Y, Zhang P . Downregulation of HMGB1 in thymoma cells affects T cell differentiation. Cent Eur J Immunol. 2023; 48(3):237-244. PMC: 10604641. DOI: 10.5114/ceji.2023.132198. View

den Bakker M, Roden A, Marx A, Marino M . Histologic classification of thymoma: a practical guide for routine cases. J Thorac Oncol. 2014; 9(9 Suppl 2):S125-30. DOI: 10.1097/JTO.0000000000000297. View

Masaoka A, Yamakawa Y, Niwa H, Fukai I, Kondo S, Kobayashi M . Extended thymectomy for myasthenia gravis patients: a 20-year review. Ann Thorac Surg. 1996; 62(3):853-9. DOI: 10.1016/s0003-4975(96)00376-1. View

Kang S, Oh J, Keun Song S, Lee J, Choi J, Kang J . Both binding and blocking antibodies correlate with disease severity in myasthenia gravis. Neurol Sci. 2015; 36(7):1167-71. DOI: 10.1007/s10072-015-2236-8. View

Aprile V, Korasidis S, Bacchin D, Petralli G, Petrini I, Ricciardi R . Thymectomy in Myasthenic Patients With Thymoma: Killing Two Birds With One Stone. Ann Thorac Surg. 2020; 112(6):1782-1789. DOI: 10.1016/j.athoracsur.2020.12.010. View

Gilhus N, Tzartos S, Evoli A, Palace J, Burns T, Verschuuren J . Myasthenia gravis. Nat Rev Dis Primers. 2019; 5(1):30. DOI: 10.1038/s41572-019-0079-y. View

10.

Ding Y, Zhou Y, Li H, Xiong Y, Yin W, Zhao L . Characteristics of immune function in the acute phase of Henoch-Schönlein purpura. Clin Rheumatol. 2021; 40(9):3711-3716. DOI: 10.1007/s10067-021-05707-6. View

11.

Chen Y, Zhang X, Wang Y, Lu C, Li J, Zhang P . Imbalance of Th17 and Tregs in thymoma may be a pathological mechanism of myasthenia gravis. Mol Immunol. 2021; 133:67-76. DOI: 10.1016/j.molimm.2021.02.011. View

12.

Zhang G, Su L, Wu W, Qiao Q, Gao S, Zhang Y . Efficacy of different doses of corticosteroids in treating severe COVID-19 pneumonia. Virol J. 2024; 21(1):74. PMC: 10967132. DOI: 10.1186/s12985-024-02345-7. View

13.

von Kempis J, Duetsch S, Reuschling N, Villiger R, Villiger P, Vallelian F . Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland. Swiss Med Wkly. 2019; 149:w20022. DOI: 10.4414/smw.2019.20022. View

14.

Berrih-Aknin S, Le Panse R . Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun. 2014; 52:90-100. DOI: 10.1016/j.jaut.2013.12.011. View

15.

Winberg L, Nielsen C, Jacobsen S . Surface complement C3 fragments and cellular binding of microparticles in patients with SLE. Lupus Sci Med. 2017; 4(1):e000193. PMC: 5387967. DOI: 10.1136/lupus-2016-000193. View

16.

Weis C, Yao X, Deng Y, Detterbeck F, Marino M, Nicholson A . The impact of thymoma histotype on prognosis in a worldwide database. J Thorac Oncol. 2015; 10(2):367-72. PMC: 4318643. DOI: 10.1097/JTO.0000000000000393. View

17.

Zhang J, Zhang Z, Zhang H, Cui Y, Chen Y, Lv P . Thymectomy in ocular myasthenia gravis-prognosis and risk factors analysis. Orphanet J Rare Dis. 2022; 17(1):309. PMC: 9361517. DOI: 10.1186/s13023-022-02454-y. View

18.

Liu A, Lin H, Liu Y, Cao X, Wang X, Li Z . Correlation of C3 level with severity of generalized myasthenia gravis. Muscle Nerve. 2009; 40(5):801-8. DOI: 10.1002/mus.21398. View

19.

Cheng J, Peng Y, Wu Q, Wu Q, He J, Yuan G . Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement. Clin Rheumatol. 2024; 43(7):2229-2236. DOI: 10.1007/s10067-024-06992-7. View

20.

Zhang J, Zhang H, Cui Y, Chen Y, Lv P, Li X . Thymectomy in thymomatous generalized myasthenia gravis: An analysis of the prognosis and risk factors. Eur J Neurol. 2023; 30(7):2012-2021. DOI: 10.1111/ene.15807. View